FGF23: A Mature Renal and Cardiovascular Risk Factor?
Authors:
- Carmine ZoccaliCarmine Zoccali
- Mahmut Ilker YilmazMYMahmut Ilker Yilmaz
- Francesca MallamaciFMFrancesca Mallamaci
- 25 May 2013
- journal article
- review article
- Published by S. Karger AG in Blood Purification
- Vol. 36 (1) , 52-57
Abstract
High FGF23 predicts renal function loss in chronic kidney disease (CKD) patients and graft failure in transplant patients. FGF23, parathyroid hormone and serum phosphate are all interrelated but among these CKD-MBD biomarkers only FGF23 is independently related with CKD progression. High FGF23 associates with endothelial dysfunction in CKD patients and in elderly individuals in the general population. Furthermore, independently of serum phosphate, high FGF23 associates with mortality and left ventricular hypertrophy in dialysis patients and with atherosclerosis in elderly individuals in the general population. FGF23 also predicts a high risk for death and cardiovascular events in predialysis CKD patients and in subjects with coronary artery disease. A recent trial in CKD patients showed that low phosphate intake associated with a phosphate binder produces a 35% decrease in plasma FGF23. Yet in this and in another trial testing several phosphate binders, FGF23 levels remained well beyond the upper limit of the normal range. Of note, in this latter study, calcification of the coronary arteries and abdominal aorta actually increased, rather than decreased, during treatment with these drugs in the face of evidence of negative phosphate balance and amelioration of hyperparathyroidism. Mechanistic studies are still needed before testing the hypothesis that FGF23 is implicated in a causal manner in cardiovascular and renal diseases. Given the modest effects of phosphate binders on serum FGF23 in CKD patients, pharmacologic interventions antagonizing the effects of this growth factor rather than phosphate-lowering interventions should be put in place to properly test this hypothesis in the clinical scenario in CKD.Keywords
This publication has 47 references indexed in Scilit:
- Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the communityKidney International, 2013
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011
- Fibroblast Growth Factor 23 (FGF23) and Alpha-Klotho Stimulate Osteoblastic MC3T3.E1 Cell Proliferation and Inhibit MineralizationCalcified Tissue International, 2011
- Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney diseaseKidney International, 2011
- A potential link between phosphate and aging—Lessons from Klotho-deficient miceMechanisms of Ageing and Development, 2010
- Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly populationAtherosclerosis, 2009
- Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the communityAtherosclerosis, 2009
- Relationship between circulating FGF23 and total body atherosclerosis in the communityNephrology Dialysis Transplantation, 2009
- Investigation of Gender Heterogeneity in the Associations of Serum Phosphorus With Incident Coronary Artery Disease and All-Cause MortalityAmerican Journal of Epidemiology, 2008
- Fibroblast Growth Factor 23 and Mortality among Patients Undergoing HemodialysisNew England Journal of Medicine, 2008